Strategy against gynecologic cancer: past, present, and future.
-Uterine Cancer Committee-



The Past trials and research results of uterine cancer committee

Nobuo Yaegashi, M.D., Ph.D. Former Chairperson, Uterine Cancer Committee

Six studies have been conducted by the uterine cancer committee since 2002, as shown in the table. Five finished studies were reported at international meetings and in journals, and two studies are now under analysis. There is no ongoing trial right now.

JGOG2041 showed the feasibility of

taxane plus platinum combination therapy, and recommended docetax-el/cisplatin (DP) and paclitaxel/carboplatin (TC) as candidates for the phase III randomized clinical study (JGOG 2043). Unfortunately, JGOG2042 was recommended for early termination based on safety concerns by the Data Monitoring Committee. JGOG2044S and

JGOG2045S have been published in Gynecologic Oncology.

The uterine cancer committee has an important mission to improve survival in patients with uterine corpus malignancies. We hope that the JGOG members will propose new world-wide attractive concepts.

(Written by Tadao Takano)

Protocol No.	Study name	Phase	Publications
JGOG2041	Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma.	П	Annals of Oncology 22; 636–642, 2011
JGOG2042	Phase II study of lrinotecan (CPT-11) in uterine leiomyosarcoma.	II	under analysis
JGOG2043	Randomized phase III study comparing doxorubicin plus cisplatin, docetaxel plus cisplatin, and paclitaxel plus carboplatin in patients with high-risk endometrial cancer.	III	under analysis
JGOG2044S	Practice pattern for postoperative management of endometrial cancer in Japan.	survey research	Gynecologic Oncology 115; 456–459, 2009
JGOG2045S	Status of surgical treatment procedures for endometrial cancer in Japan.	survey research	Gynecologic Oncology 105; 325–328, 2007

JGOG International Newsletterより許可を得て掲載